NCT00381797View on ClinicalTrials.gov

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Childhood Cerebral Anaplastic AstrocytomaChildhood OligodendrogliomaChildhood Spinal Cord NeoplasmRecurrent Childhood Brain Stem GliomaRecurrent Childhood EpendymomaRecurrent Childhood Medulloblastoma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

RADIATION

Fludeoxyglucose F-18

Undergo fludeoxyglucose F18 PET

DRUG

Irinotecan Hydrochloride

Given IV

Trial Locations (11)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

27710

Duke University Medical Center, Durham

38105

Pediatric Brain Tumor Consortium, Memphis

St. Jude Children's Research Hospital, Memphis

60611

Lurie Children's Hospital-Chicago, Chicago

77030

Texas Children's Hospital, Houston

94115

UCSF Medical Center-Mount Zion, San Francisco

98105

Seattle Children's Hospital, Seattle

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00381797 - Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | Biotech Hunter | Biotech Hunter